SciELO - Scientific Electronic Library Online

vol.49 número3Characterization of snakebite cases attended by the drug and poison research and information center ( CIEMTO) in Medellin, Colombia during 2016Economic costs of acute respiratory infection in a municipality of Colombia índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google


Revista de la Universidad Industrial de Santander. Salud

versão impressa ISSN 0121-0807


HENAO Z, Yuly; BOTERO S, Piedad L; PARRADO F, Ilsa Y  e  AMARILES, Pedro. Concordance in the use of teriparatide or zoledronic acid in patients with osteoporosis with international recommendations, in a health company of Colombia. Rev. Univ. Ind. Santander. Salud [online]. 2017, vol.49, n.3, pp.458-468. ISSN 0121-0807.


Bisphosphonates are the first-line treatment of osteoporosis in which zoledronate is the most effective. Teriparatide (anabolic agent), due to high cost, should be restricted to the treatment of the most affected patients and after adequate treatment with bisphosphonates.


To establish the percentage of patients with osteoporosis, in treatment with teriparatide or zoledronic acid in Colombia, that meet international organizations recommendations.


Retrospective drug utilization study, January 2012-December 2015, in patients with osteoporosis and treatment with teriparatide or zoledronic acid. The socio-demographic and clinical information and the degree of concordance of teriparatide or zoledronic acid use with recommendations from three international clinical guidelines were reviewed: National Osteoporosis Foundation, National Institute for Health and Clinical Excellence, and Scottish Intercollegiate Guidelines Network.


103 patients were included, average age in years (standard deviation) 78 (10.4), 74.8% women. Postmenopausal osteoporosis (61.2%) and unspecified osteoporosis (20.4%), both with or without pathological fracture, were the main diagnoses. In 36.9%, the use of teriparatide and zoledronic acid was accord with the guidelines recommendations revised. The use of these drugs in diagnoses different to postmenopausal osteoporosis (43.7%) or initial pharmacotherapy (36.9%) were the main causes for concordance absence.


Only 36.9% of the reviewed cases, the use of teriparatide or zoledronic acid was accord with international organizations guideliness. Concordance absence is due especially both to the use in diagnoses different to postmenopausal osteoporosis and initial pharmacotherapy.

Palavras-chave : osteoporosis; teriparatide; bone density conservation agents; drug utilization; pharmacoepidemiology.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )